Table 2.
Treatments received before and after enrolment
| Remdesivir group (n=158) | Placebo group (n=78) | ||
|---|---|---|---|
| Time from symptom onset to starting study treatment, days* | 11 (9–12) | 10 (9–12) | |
| Early (≤10 days from symptom onset) | 71/155 (46%) | 47 (60%) | |
| Late (>10 days from symptom onset) | 84/155 (54%) | 31 (40%) | |
| Receiving injection of interferon alfa-2b | 46 (29%) | 30 (38%) | |
| Receiving lopinavir–ritonavir | 44 (28%) | 23 (29%) | |
| Vasopressors | 25 (16%) | 13 (17%) | |
| Renal replacement therapy | 3 (2%) | 3 (4%) | |
| Highest oxygen therapy support | |||
| Non-invasive mechanical ventilation | 14 (9%) | 3 (4%) | |
| Invasive mechanical ventilation | 11 (7%) | 10 (13%) | |
| Extracorporeal membrane oxygenation or mechanical ventilation | 2 (1%) | 0 | |
| Antibiotic | 142 (90%) | 73 (94%) | |
| Corticosteroids therapy | 102 (65%) | 53 (68%) | |
| Time from symptom onset to corticosteroids therapy, days | 9 (7–11) | 8 (6–10) | |
| Duration of corticosteroids therapy, days | 9 (5–15) | 10 (6–16) | |
Data are median (IQR) or n (%).
*
Three patients did not start treatment so are not included in time from symptom onset to start of study treatment subgroup analyses.